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We read with interest the paper by Palms and Jacob describing risk factors for re-admission 
following an episode of Outpatient Parenteral Antimicrobial Therapy (OPAT) care[1]. In the 
context of a large American hospital the authors describe a re-admission rate to hospital of 
18% within 30 days of discharge on OPAT. Overall 73% of patients were seen in clinic 
following discharge, of which only 52% were seen in a dedicated OPAT clinic. In this setting 
active follow-up in any clinic was associated with a significantly reduced risk of readmission 
(OR 0.1 95% CI 0.06-0.17). 
 
The model of care described by Palms and Jacob differs from that delivered by many United 
Kingdom OPAT services. Whilst in both settings, acceptance onto OPAT requires 
consultation with an Infectious Diseases clinician, follow-up in a multi-disciplinary OPAT 
clinic is routine in the UK National Health Service in keeping with UK good practice 
guidelines for OPAT [2]. For comparison, we reviewed rates of readmission for patients 
accepted onto our OPAT service at University College London Hospitals (UCLH), a large 980-
bed tertiary hospital in the United Kingdom. Patients accepted onto the OPAT service at 
UCLH are reviewed weekly at a dedicated OPAT clinic and a multidisciplinary meeting[3,4]. 
We extracted data from our prospective OPAT database [5] on the criteria for OPAT 
eligibility, duration of OPAT, number of outpatient clinical reviews and the number and 
reasons for readmission.  When calculating the number of follow-up review numbers, we 
excluded  phone consultations and in the weekly MDT meeting.  
 
Over the period 2016 to 2019 a total of 826 patients were managed through the OPAT 
service at UCLH. The most common reasons for OPAT were skin and soft tissue infections 
(240, 29.1%), bone and joint infections (173, 20.9%), and urinary tract infections (108, 
13.1%) (Table 1). Patients received OPAT for a median of 7 days (IQR 3 – 17 days) and 
received a median of three reviews during their OPAT episode (IQR 1-4). Only 3.8% were 
readmitted to hospital and mortality was only 0.25%. Of patients requiring readmission, the 
majority were for reasons unrelated to their primary infective diagnosis (n = 16, 51.6%) 
(Table 1). We previously described markedly lower rates of adverse events in our service 
compared with data reported in US-based OPAT care [4,6]. Together our data suggest that 
the regular monitoring provided to patients through UK OPAT services reduces OPAT 
patients’ complication and readmission rates .   
 
OPAT undoubtedly offers an effective model to avoid inpatient admissions and to save 
costs. However delivering OPAT care is complex and requires ongoing input from a 
dedicated multidisciplinary team and review in a dedicated outpatient clinic.  
 
OPAT services are evolving in light of data from studies such as OVIVA demonstrating a 
reduced requirement for intravenous antibiotics [7,8]. However, as with other areas of 
complex infection management, where specialist consultation improves outcome [9], our 
data support the notion that regular outpatient review, regardless of the route by which 
antibiotics are delivered, will remain a cornerstone of successful clinical outcomes of these 
patients[10].  
 






/cid/advance-article-abstract/doi/10.1093/cid/ciaa132/5729890 by London School of H
ygiene & Tropical M





1.  Palms DL, Jacob JT. Close Patient Follow-up Among Patients Receiving Outpatient Parenteral 
Antimicrobial Therapy. Clin Infect Dis 2020; 70:67–74.  
2.  Chapman ALN, Patel S, Horner C, et al. Updated good practice recommendations for 
outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK. JAC-Antimicrob 
Resist 2019; 1. Available at: https://academic.oup.com/jacamr/article/1/2/dlz026/5554098. 
Accessed 23 December 2019. 
3.  Dabrowski H, Wickham H, De S, et al. Clinical outcomes of teicoplanin use in the OPAT 
setting. Int J Antimicrob Agents 2020; :105888.  
4.  Underwood J, Marks M, Collins S, Logan S, Pollara G. Intravenous catheter-related adverse 
events exceed drug-related adverse events in outpatient parenteral antimicrobial therapy. J 
Antimicrob Chemother 2019; 74:787–790.  
5.  Marks M, Pollara G, Miller D, et al. elCID: An electronic Clinical Infection Database to support 
integrated clinical services and research in infectious diseases. J Infect 2015; 71:402–405.  
6.  Keller SC, Williams D, Gavgani M, et al. Rates of and Risk Factors for Adverse Drug Events in 
Outpatient Parenteral Antimicrobial Therapy. Clin Infect Dis Off Publ Infect Dis Soc Am 2018; 66:11–
19.  
7.  Li H-K, Rombach I, Zambellas R, et al. Oral versus Intravenous Antibiotics for Bone and Joint 
Infection. N Engl J Med 2019; 380:425–436.  
8.  Marks M, Bell LCK, Jones I, et al. Clinical and economic impact of implementing OVIVA 
criteria on patients with bone and joint infections in OPAT. Clin Infect Dis Available at: 
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciz991/5585680. Accessed 11 
October 2019. 
9.  Fries BL, Licitra C, Crespo A, et al. Infectious diseases consultation and the management of 
Staphylococcus aureus bacteremia. Clin Infect Dis Off Publ Infect Dis Soc Am 2014; 58:598–599.  
10.  Seaton RA, Ritchie ND, Robb F, Stewart L, White B, Vallance C. From ‘OPAT’ to ‘COpAT’: 
implications of the OVIVA study for ambulatory management of bone and joint infection. J 








/cid/advance-article-abstract/doi/10.1093/cid/ciaa132/5729890 by London School of H
ygiene & Tropical M





Table 1. Clinical characteristics of 826 episodes of OPAT care at a tertiary referral 




Skin and Soft Tissue 
Infection 240 (29.1%) 
Bone and Joint Infections 
including Prosthetic Joint 
Infection 173 (20.9%) 
Urinary Tract Infection 108 (13.1%) 
Respiratory Infection 65 (7.9%) 
Bacteraemia 49 (5.9%) 
Endocarditis 28 (3.4%) 
Malignant Otitis Externa 27 (3.3%) 
Central Nervous System 
Infection 26 (3.1%) 
Other 85 (10.3%) 
Readmission 
No 792 (95.3%) 
Yes 31 (4.7%) 
Reason for 
Readmission 
Unrelated to Original 
Infection 16 (51.6%) 
Relapse of Original Infection 11 (35.5%) 
New Infection 3 (9.7%) 
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